Compare ECO & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECO | STOK |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2023 | 2019 |
| Metric | ECO | STOK |
|---|---|---|
| Price | $54.08 | $29.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $42.00 | $39.20 |
| AVG Volume (30 Days) | 395.4K | ★ 462.9K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.12% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | N/A | $77.49 |
| P/E Ratio | $18.60 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $21.27 | $9.09 |
| 52 Week High | $58.45 | $40.22 |
| Indicator | ECO | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 34.09 |
| Support Level | $52.70 | $25.21 |
| Resistance Level | $57.87 | $35.11 |
| Average True Range (ATR) | 2.22 | 1.60 |
| MACD | -0.29 | -0.28 |
| Stochastic Oscillator | 23.48 | 19.11 |
Okeanis Eco Tankers Corp is an international owner and operator of a fleet of tanker vessels used for the transportation of crude oil. Its fleet consists of modern Suezmax and VLCC tankers that are designed in accordance with eco-efficiency standards, including features such as reduced fuel consumption, exhaust gas cleaning systems, and ballast water treatment systems. All of the company's revenue is derived from a single segment, the crude oil tanker segment. Geographically, the maximum revenue is generated from Europe, and the rest from Asia, North America, and South America.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.